Neoadjuvant chemotherapy prior to vascular resection in pancreaticoduodenectomy for pancreas cancer

Background: Neoadjuvant chemotherapy (NC) is given in pancreatic ductal adenocarcinoma (PDAC) prior to pancreaticoduodenectomy to increase the R0 resection rate and improve survival. Vascular resection (VR) is associated with more aggressive disease and adds considerable morbidity to pancreaticoduodenectomy. This study evaluated the impact of NC and VR on outcomes after pancreaticoduodenectomy.